NGL FINECHEM
|
|
| BOM : 524774     NSE : NGLFINE     | |
| LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Upward Pledged Shares : None or < 25% |
Jun 02,2026 |
|
Price(EOD): ₹ 2,662.10
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 1,650.50 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NGL FINECHEM | -5.8% | 18.6% | 121.3% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.8% | -1% | 6.7% |
| DIVIS LABORATORIES | -3.3% | 0.4% | -2.2% |
| TORRENT PHARMACEUTICALS | -3.1% | 2.9% | 36.9% |
| CIPLA | -2.7% | 5.3% | -6.1% |
| DR REDDYS LABORATORIES | -4.1% | -3.7% | 3.7% |
| MANKIND PHARMA | -5% | 2.3% | -5.4% |
| LUPIN | -0.6% | -2.4% | 14.7% |
| ZYDUS LIFESCIENCES | -0.2% | 20.8% | 18.8% |
FUNDAMENTAL ANALYSIS OF NGL FINECHEM
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF NGL FINECHEM
 | Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
34.23
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 48.04 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] 5
P/B Calculated based on Book Value of Rs 329.24 Cr
[Latest Year - Mar2026 - Consolidated Results ] 3.28
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 501.19 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
338% 20% 22% |
SHARE PRICE MOMENTUM OF NGL FINECHEM
NGL FINECHEM vs SENSEX
DEBT OF NGL FINECHEM
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2025 2024 2023 Avg_3yrs |
0.27 0.13 0.14 0.18 |
0.27 0.13 0.15 0.18 |
|
[Last Annual Data : Mar2025]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF NGL FINECHEM
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2026 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF NGL FINECHEM
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
17.04% -4.04% -13.82% -14.05% |
57.14% 238.87% 1580.47% 2383.61% |
| QtrlyTrend |
2 | |
| Latest Qtr: Mar2026 | ||
| Quarterly Result Analysis → | ||
NGL FINECHEM related INDICES
You may also like the below Video Courses
FAQ about NGL FINECHEM
Is NGL FINECHEM good for long term investment?
As on Jun 02,2026, the Fundamentals of NGL FINECHEM look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of NGL FINECHEM . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is NGL FINECHEM UnderValued or OverValued?
As on Jun 02,2026, NGL FINECHEM is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of NGL FINECHEM ?
As on Jun 02,2026, the Intrinsic Value of NGL FINECHEM is Rs. 2,187.44 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 607.94
Fair Value [Median EV / Sales Model] : Rs. 2,227.27
Fair Value [Median Price / Sales Model] : Rs. 2,187.44
Estimated Median Fair Value of NGL FINECHEM : Rs. 2,187.44
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.